The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Official Title: A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation
Study ID: NCT01078662
Brief Summary: To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Melbourne, , Australia
Research Site, Randwick, , Australia
Research Site, Köln, , Germany
Research Site, Haifa, , Israel
Research Site, Jerusalem, , Israel
Research Site, Jerusalem, , Israel
Research Site, Petah Tikva, , Israel
Research Site, Madrid, , Spain
Research Site, Lund, , Sweden
Name: Jane Robertson, BSc, MBCHB, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Bella Kaufman, MD
Affiliation: Chaim Sheba Medical Centre, Tel Hashomer, Israel
Role: PRINCIPAL_INVESTIGATOR